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Nowadays methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common multidrug resistant bacteria both in
hospitalsandinthecommunity.Inthelasttwodecades,therehasbeengrowingconcernabouttheincreasingresistancetoMRSAof
themostpotentantibioticglycopeptides.MRSAinfectionposesaseriousproblemforphysiciansandtheirpatients.Photosensitizer-
mediated antimicrobial photodynamic therapy (PDT) appears to be a promising and innovative approach for treating multidrug
resistant infection. In spite of encouraging reports of the use of antimicrobial PDT to inactivate MRSA in large in vitro studies,
there are only few in vivo studies. Therefore, applying PDT in the clinic for MRSA infection is still a long way off.
1. Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) was first
reported in 1961 [1], and since then MRSA has undergone
rapid evolutionary changes and epidemiologic expansion.
Th ep r o b l e mo fM R S Ai n f e c t i o nh a sr a p i d l yg r o w ni nt h e s e
years. Currently, MRSA results in more than one-half of
the nosocomial infections with S. aureus strains in most
countries [2]. MRSA accounts for approximately 60% of
clinical S. aureus strains isolated from intensive care units in
theU nitedStates[3].MostpeopleacquireMRSAinahospital
setting (HA-MRSA). These strains establish an ecological
niche in the hospital environment and are easily transmitted
between patients and from doctor to patient [4]. In recent
years, community-acquired MRSA (CA-MRSA) strains have
emerged, where they are rapidly becoming the dominant
pathogens in the community [5].
MRSA has altered penicillin-binding proteins (PBPs)
with reduced affinity to penicillin and other available 𝗽-
lactam antibiotics [6]. For a long time, glycopeptide antibi-
otics, especially Vancomycin, were extensively used in clin-
ical practice. In the last two decades, there has also been
growing concern about the increasing glycopeptide mini-
mum inhibitory concentrations (MICs) for MRSA [7, 8].
Therefore, MRSA poses a serious problem for clinicians and
patients. Due to the limited therapeutic options, infections
caused by these resistant strains are usually difficult to treat.
The problem of a relatively rapid acquisition of antibiotic
resistance of MRSA is complicated by the relatively long-
time period needed for the development of antibiotics with
new mechanisms of action. As it can be anticipated that the
development of resistance will continue in the coming years,
it is just a question of time until the bacterium develops
resistance towards newly developed antibiotics. Therefore,
thenecessityexistsforanimmediateandcontinualsearchfor
alternative methods against MRSA towards which no resis-
tancecandevelop.Oneofthemostpromisingandinnovative
approaches in this respect is antimicrobial photodynamic
therapy (PDT) [9–11]. This therapeutic approach involves
the administration of a photosensitizer, usually a porphyrin-
based compound, which, upon photoactivation with visible
light of appropriate wavelength, generates reactive oxygen
species(ROS),suchassingletoxygenandfreeradicals,which
are cytotoxic to bacterial cells.2 BioMed Research International
This paper summarizes the mechanism of antimicrobial
PDT and the progress of preclinical studies of antimicrobial
PDT towards MRSA and identifies the potential applications
to MRSA infection that may become valuable in the clinic.
2. Mechanisms of Antimicrobial PDT
Although the exact mechanism of PDT is not known in
detail, there are two possible molecular mechanisms that are
believed to play central roles in antimicrobial PDT. Both
mechanisms cannot preclude the prerequisites for PDT: the
sufficient presence of molecular oxygen, photosensitizer, and
light of the appropriate wavelength. In the type I mechanism,
free radicals are formed that react with lipids and proteins
l e a d i n gt oac h a i nr e a c t i o nt h a tp r o d u c e sm o r eo x i d a t i o n
products [12] .I nt h et y p eI Im e c h a n i s m ,e n e r g yf r o mt h e
tripletstateofthephotosensitizer,formedby lightexcitation,
is transferred to the molecular oxygen, resulting in the gen-
eration of highly reactive singlet oxygen. The singlet oxygen
can directly react with cellular molecules in its immediate
vicinity and also creates further oxygen radicals [13]. It is
generallyacceptedthattheproductionofsingletoxygenplays
the key role in PDT for infection and other diseases [11]. The
ROS from both mechanisms react inside the bacterial cell
or in vicinity and induce necrosis or apoptosis of bacteria
(Figure 1).
ROSfromphotosensitizer-mediatedantibacterialtherapy
c a nc a u seb a ct e ri a ll e th a li n j u ryb ym e a n so fd a m a g et oD N A
and the cytoplasmic membrane. Treatment of bacteria with
v a r i o u sp h o t o s e n s i t i z e r sa n dl i g h tl e a d st ob o t hs i n g l e -a n d
double-stranded DNA break-in and the disappearance of the
plasmid supercoiled fraction, which has been detected in
both Gram-positive and Gram-negative species after PDT
[14, 15]. Some photosensitizers that more easily intercalate
into double-stranded DNA can cause more damage [16].
Evidence also shows that guanine residues of DNA are the
most susceptible to oxidation by ROS [16]. However, DNA
d a m a g em i g h tn o tb et h ep r i m er e a s o nf o rb a c t e r i a lc e l l
d e a t h ,b e c a u s et h ed a m a g em a yb ea b l et ob er e p a i r e db y
various DNA repairing systems [17] .D u et ot h eu s u a l l y
lipophilicnatureofmanyphotosensitizers,theytendtolocate
primarily in membranes consisting of lipid double layers.
Therefore,anothercriticaldamage site by ROS during PDT is
the cytoplasmic membrane, which allows leakage of cellular
contents or inactivation of membrane transport systems and
enzymes. The alterations of cytoplasmic membrane proteins,
disturbance of cell-wall synthesis and the appearance of a
multilamellarstructureneartheseptumofdividingcells,and
loss of potassium ions from the cells have been reported [18–
20].
The photosensitizer is the key component in the pho-
tosensitization process because it absorbs light and initiates
formation of toxic species. Photosensitizers are mainly from
the following classes: porphyrins, chlorines, phthalocyanine,
Rose Bengal, phenothiazines, and acridines. The structures
of porphyrins, chlorines, and phthalocyanine are based on
t h et e t r a p y r r o l en u c l e u s ,w h e r e a st h eo t h e r sh a v ed i ff e r e n t
molecular frameworks [21]. These photosensitizers induce
varying photodynamic activities towards Gram-positive and
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Figure 1: The mechanism of antibacterial PDT. Photosensitizers
can be preferentially uptaken by bacteria, accumulating inside
the bacteria and in the cytoplasm membranes, or in the vicinity.
Upon absorption of a photon by the ground-state photosensitizer
after light illumination, the reactive oxygen species (ROS) will be
generated from two alternative pathways: type I mechanism and
type II mechanism. The generated ROS then react rapidly with
their environment depending on the localization of the excited
photosensitizer: bacteria cell wall, lipid membranes, proteins and
enzymes, and nucleic acids. The reaction of these important cellular
components may result in necrosis or apoptosis of the bacteria at
last.
Gram-negative bacteria [21]. Due to structural differences
o ft h eo u t e rb a c t e r i a lc e l lw a l lo fG r a m - p o s i t i v ea n dG r a m -
negative bacteria, differences naturally exist with respect
to the efficacy of the various photosensitizers. The 40–
80nm thick outer cell wall and up to 100 peptidoglycan
layers of Gram-positive bacteria do not represent an effective
permeability barrier. In contrast, the outer membrane of
Gram-negativebacteriawithabilamellarmembranecovering
theonly3nmthickpeptidoglycanlayerisabletoimpedepho-
tosensitizer diffusion considerably, especially the negatively
charged or neutral photosensitizers. Various strategies have
been developed to cross this barrier, such as pretreatment
with EDTA or polymyxin B, which make the outer wall
of bacteria more permeable and allow photosensitizer to
penetrateandaccumulateonthecytoplasmicmembrane[22,
23]. In contrast to the low penetration of negatively charged
and neutral photosensitizers, the positively charged pho-
tosensitizers are photodynamically active even without the
addition of a penetration booster [24–26]. Not only resting
orvegetativecellsbutalsoBacillussporeshavebeenshownto
be inactivated using photodynamic administration [27]. As a
resultofthehighreactivityofsingletoxygenwithproteins,its
lifespan in a cellular environment is very short, which results
in a very short diffusion distance. Therefore, the effectiveness
of a photosensitizer depends not only on the amount taken
up, but also on the location of the photosensitizer at the time
p o i n to fi r r a d i a t i o n[ 28].
3. Inactivating MRSA by PDT
With various photosensitizers and the appropriate wave-
l e n g t hl i g h t ,M R S Ah a sb e e no b s e r v e dt ob ed r a m a t i c a l l yBioMed Research International 3
inactivated in a serial of in vitro studies. Wilson and Pratten
[29] found that cultured MRSA was inactivated significantly
by aluminum disulphonated phthalocyanine and light even
in the presence of horse serum. Eight isolates of MRSA
frompatientsweredemonstratedtobecompletelyeradicated
following 15min exposure to a 632.8nm HeNe laser in
t h ep r e s e n c eo f5 0𝜇g/mL photosensitizer toluidine blue O
(TBO) under in vitro conditions [30]. No significant effect
was observed on the MRSA isolates exposed to the laser
alone. In another study [31], light-activated antimicrobial
agent aluminium disulphonated phthalocyanine (AlPcS 2)
was used to determine whether 16 epidemic MRSA strains
could be inactivated by antimicrobial PDT. The results indi-
cated that all 16 strains were susceptible to inactivating by
PDT. The bactericidal effect was dependent on the AlPcS 2
concentration and the light dose, and inactivation was not
affected by the growth phase of the organism. Scavengers of
singlet oxygen and free radicals protected the bacteria from
inactivation [31].
For better simulating in vivo condition, an artificial
skin construct was applied to test whether methylene blue
(MB) mediating PDT could inactivate MRSA growing on
it [32]. The artificial skin was composed of human-derived
epidermal keratinocytes and dermal fibroblasts cultured at
an air/media interface to form a stratified model of full
thickness epithelialized human skin. PDT combined with
MB treatment produced a significant reduction (5.1logs)
from control immediately after treatment and the effect
was sustained over multiple days, while application of MB
a l o n er e s u l t e di ns m a l lr e d u c t i o ni nM R S Av i a b i l i t yf r o m
nontreated control [32].
In another study, penetration and antibacterial efficacy
of a cationic porphyrin photosensitizer XF73 against MRSA
was examined on an ex vivo porcine skin model [33]. The
researchers performed both preincubation of bacteria in
solution with XF73 followed by subsequent application on
the ex vivo porcine skin and application of bacteria on the
skinfollowedbyanincubationwithXF73.Thelocalizationof
XF73 was restricted to the stratum corneum. Preincubation
of S. aureus demonstrated a high photoinactivation efficacy
(>3logs reduction) after irradiation, while illumination after
XF73 was delivered to the bacteria on the skin resulted in an
approximately 1log growth reduction independently of the
antibiotic resistance pattern of the S. aureus strainsused [33].
Histological evaluations of untreated and treated skin areas
upon irradiation within 24h did not show significant degree
of necrosis or apoptosis [33].
Over40differentvirulencefactorsincludingawiderange
of enzymes and toxins have been identified in S. aureus,
which are involved in almost all processes from colonization
of the host to nutrition and dissemination [34, 35]. How-
ever, in general, conventional antibiotics have no effect on
inactivating these virulences. The activities of V8 protease,
𝗼-haemolysin, and sphingomyelinase expressed by epidemic
MRSA16 were identified to be inhibited in a dose-dependent
manner (1–20𝜇M) by exposure to laser light in the presence
of MB [36]. Moreover, inactivation of 𝗼-haemolysin and
sphingomyelinase is not affected by the presence of human
serum, indicating that PDT may be effective against these
toxins in vivo [36].TheabilityofPDT toreducethevirulence
of MRSA, as well as effectively inactivating the organism,
would represent a significant advantage over conventional
antibiotic strategies.
Although there have been encouraging reports of the
use of antimicrobial PDT to inactivate MRSA in large in
vitro studies, there have been relatively few reports of their
use to treat MRSA infection in vivo. And all the current
in vivo studies are confined within local MRSA infection
on rodent models. A mouse model of skin abrasion wound
infected with bioluminescent strain of MRSA Xen31 was
developed [37]. This bioluminescent strain allows the real-
time monitoring of infection in mouse wounds. PDT was
performedwiththecombinationofaseriesofconcentrations
of photosensitizer polyethylenimine- (PEI-) ce6 and a series
of doses of noncoherent red light 30 minutes after bacterial
inoculation.PDTresultedin2.7logsofinactivationofMRSA
as judged by loss of bioluminescence in mouse skin abrasion
woundsandacceleratedwoundhealingby8.6dayscompared
with the untreated infected wounds [37]. A tetracationic
Zn(II)phthalocyaninederivativewasalsoshowntoinactivate
MRSA, inhibit regrowth, and accelerate wound healing by
using the mouse skin abrasion model [38]. Simonetti et
al. [39] established full-thickness wounds with diameter of
0.8cm, which were then inoculated with 5 × 10
7 CFU of
MRSA in the back subcutaneous tissue of BALB/c and CD1
mice. A strong reduction of bacterial counts (3logs) was
observed in mice treated with RLP068/Cl and illumination
in comparison with infected untreated mice 2 days after
infection. By day 9, a comparable and significant reduc-
tion of bacterium and a complete reepithelialization were
f o u n di nm i c et r e a t e dw i t hR L P 0 6 8 / C lo rw i t ha n t i b i o t i c
teicoplanin [39]. A 25-fold reduction in the number of
epidemicMRSA16treatedwith100𝜇g/mLofMBand670nm
laser light (360J/cm
2) was achieved in another mouse skin
wound model [40].
MRSA arthritis is another animal model chosen to test
the effectiveness of PDT for MRSA infection in vivo. A
murine MRSA arthritis model showed that approximately
30% of intra-articular leukocytes, mainly neutrophils, died
immediatelyafterPDT[41].Afurtherdecreaseinthenumber
of intra-articular leukocytes and atrophy of the synovial
tissue were seen 24h after PDT. The isolated peripheral
neutrophils presented significant affinity to Photofrin and
showed significant morphological damage after PDT with
Photofrin [41]. These results indicated that PDT might not
behighlyeffectivefortreatingMRSAarthritis,becauseintra-
articular neutrophils and synovial tissue were also injured
by PDT. In order to maximize bacterial inactivation and
minimize inactivation of host neutrophils, an intra-articular
injection of Photofrin instead of intravenous administration
was used and the light dosimetry was optimized to treat
arthritis induced by MRSA infection [42]. Each animal
received a knee injection with MRSA (5 × 10
7 CFU) fol-
lowed 3 days later by 1mg of Photofrin and 635nm illu-
mination with a range of fluences within 5 minutes. The
greatest reduction of MRSA was seen with a fluence of
20J/cm
2, whereas lower antibacterial efficacy was observed4 BioMed Research International
with fluences that were either lower or higher. Consistent
with these results, a significantly higher concentration
of macrophage inflammatory protein-2 (a CXC chemokine)
and greater accumulation of neutrophils were seen in the
infected knee joint after PDT with a fluence of 20J/cm
2
compared to fluences of 5 or 70J/cm
2 [42]. These results
indicatethatPDTformurineMRSAarthritisrequiresappro-
priate light dosimetry to simultaneously maximize bacterial
inactivation and neutrophil accumulation into the infected
site,whiletoolittlelightinactivatessufficientbacteriaandtoo
much light inactivates neutrophils and damages host tissue
as well as bacteria and allows bacteria to grow unimpeded by
host defense.
4. Modification on Charge and
Structure of Photosensitizers
A potential photosensitizer for antimicrobial PDT must have
appropriatephotophysicalproperties,suchasalargeandlong
wavelength absorption band and a high quantum yield for
the generation of both long-lived triplet excited state and
cytotoxic ROS species. It also has to be water-soluble and
must have a high affinity to microbial cells and a low affinity
to host cells. These characteristics are strongly related to the
presence of cationic charges in the molecular structure.
Several groups [9, 43, 44] observed that photosensi-
tizer charge and structure might be important factors in
determining the success of antimicrobial PDT, especially
when applied on negative surface charge of microorgan-
isms like Gram-negative bacteria. Meso-substituted tetrahy-
droporphyrin tetratosylat (BL1065) was reported to acquire
the ability to bind both Gram-positive (MRSA) and Gram-
n e g a t i v eb a c t e r i a lc e l le n v e l o p em o r es t r o n g l yt h a nt h e
dianionic chlorine BLC1013, resulting in better efficiency of
photoinactivation [45].
Foley et al. [46] demonstrated that replacement of the
oxygenatominphotosensitizer5-(ethylamino)-9-diethylam-
inobenzo[a]phenoxazinium chloride (EtNBA) with sul-
fur and selenium afforded thiazinium (EtNBS) and sele-
nazinium (EtNBSe) analogues that had similar water solu-
bility, lipophilic character, and uptaking rate. But this small
change on the molecule gave EtNBS and EtNBSe better
antimicrobial efficacy than their chalcogen analogue EtNBA
mainly due to higher triplet quantum yield. Replacing the
central oxygen atom with a somewhat heavier sulfur atom
resulted in a small but significant increase in the triplet yield
(0.03)andthatasexpectedthereplacementbyamuchheavier
selenium atom resulted in a dramatic improvement in the
triplet yield (0.78) [46]. It is well known that incorporating a
heavier atom into a molecule with a low intrinsic intersystem
crossing rate constant will increase the probability of such
transitions roughly in proportion to the square of the spin-
orbit coupling constant of the atom where the transition
occurs [47].
In another report [48], two EtNBS derivatives were
synthesized, each functionalized with a different side-chain
end-group, alcohol or carboxylic acid. There were no signif-
icant changes in absolute quantum yield of singlet oxygen
formation, and both derivatives were phototoxic to S. aureus
29213, but the carboxylic acid derivative was nontoxic to
E. coli 25922. This suggests that small functional groups
of photosensitizer could achieve Gram-type-specific pho-
totoxicity through altering the photodynamic activity of
photosensitizer and deserve further exploration in a larger
numberofrepresentativestrainsofeachGramtypeincluding
MRSA.
5. New Drug Delivery Strategies Design
For antimicrobial PDT to be of clinical use, effective delivery
methods for both light and photosensitizers to the site of
actionarenecessary.Duetolimitedlightpenetrationthrough
tissue, clinical antimicrobial PDT will be necessarily limited
t oa r e a so ft h eb o d yw h e r el i g h tc a nb ed e l i v e r e dr e l a t i v e l y
easily, such as the skin and body cavities, as opposed to
systemic infections such as bacteremia [49]. In contrast to
conventional high irradiance treatments, recent preclinical
and clinical photodynamic studies have focused on low
irradiance schemes [50–52], which consume less oxygen
than high irradiance. Compared with light and oxygen
delivery, photosensitizer delivery system seems much more
complicated. Researchers focused on drug delivery strategies
for efficient but specific therapy.
Currently,photosensitizersunderinvestigationateithera
preclinicalorclinicallevelaresystemicallyadministeredafter
incorporation into lipophilic delivery systems, such as lipo-
somes, oil emulsions, or cyclodextrin inclusion complexes
in order to minimize precipitation in the bloodstream or
aggregation in a polar milieu, which decreases PDT thera-
peutic efficiency [53, 54]. As for MRSA, an enhanced inac-
tivation of MRSA by a liposome-delivered photosensitizer
was demonstrated compared with the free dye [55]. Hemato-
porphyrin was embedded in fluid cationic vesicles composed
of the monocationic lipid N-[1-(2.3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methylsulfate, which yields an
endocellular concentration of photosensitiser much higher,
yet promotes a tighter binding and a more efficient photoin-
activation of MRSA.
The use of polymeric micelles as vehicles of photosensi-
tizers is another very promising approach for photodynamic
therapy [56–58]. The polymeric micelle delivery system
may improve drug solubility and prevent the formation of
aggregates in the aqueous medium. Compared to the use of
liposomes, preparation of polymeric micelles can be much
less expensive and simpler. In a recent study, photosensi-
tizer hematoporphyrin was encapsulated with liposomes and
micellesbythereversed-phaseevaporationmethod,andboth
micelle and liposome delivered hematoporphyrin induced
completeeradicationoftheGram-positivepathogensinclud-
ing both MSSA and MRSA [59]. The hematoporphyrin dose
completelyeradicatingpathogensusingmicelleandliposome
was significantly lower than the dose required when using
the nonencapsulated hematoporphyrin. The photodynamic
inactivation effect of the hematoporphyrin encapsulated in
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encapsulated in liposomes at lower hematoporphyrin doses
[59].
In a different approach, an optimised formulation
(8.0%w/w poly(vinyl alcohol), 2.0%w/w borax) of hydrogel
was synthesized with 1.0mg/mL of the photosensitizers MB
and meso-tetra(N-methyl-4-pyridyl)porphine tetra tosylate
(TMP), both of which were found to be phototoxic to
planktonic and biofilm-grown MRSA [60]. Furthermore,
n e w b o r nc a l fs e r u m ,w h i c hw a su s e dt os i m u l a t et h ec o n -
ditions prevalent in an exuding wound, did not adversely
affect the properties of the hydrogels and had no signif-
icant effect on TMP-mediated photodynamic inactivation
of MRSA, despite appreciably reducing the fluence rate of
incident light. Topically applied to treat wound infection,
hydrogels loaded with photosensitizers possess the ability to
flow into and produce intimate contact with wounds even
heavily exuding wounds, whilst their dilated structure allows
for intact removal once the treatment is completed. These
characteristics may facilitate clinical use of photodynamic
therapy.
6. Targeted Antimicrobial PDT of MRSA
One possible problem with the use of light activated antimi-
c r o b i a la g e n t si st h a tt h eR O Sp r o d u c e dd u r i n gt h ep r o c e s s
have the potential to damage neighboring host cells. There is,
therefore, great interest in developing methods of targeting
the photosensitizer of the infecting organism. The challenge
in antimicrobial PDT is to find a therapeutic window, in
which hazardous bacteria are efficiently inactivated without
harming the surrounding tissue and disturbing the local
microenvironment at a given concentration and light dose.
The ability to confine activation of the photosensitizer by
restricting illumination to the bacteria allows for a certain
degree of selectivity towards these cells. Improved selec-
tivity with preferential bacterial uptake of photosensitizer
throughmodificationofphotosensitizerisanotherpromising
approach. To date, methods of targeting photosensitizers
specifically to a certain type of microorganism include
antibody conjugation [61, 62], attachment of peptides [63],
employing bacteriophages [64], and taking advantage of the
resistance mechanism of microorganisms [65].
A n t i b o d yc o n j u g a t e dw i t hv a r i o u sp h o t o s e n s i t i z e r sw a s
reported as a very promising targeting PDT [66–68]. As for
antibacterialPDT,alethalphotosensitizationofMRSAusing
an immunoglobulin G-tin(IV)chlorine e6 conjugate as the
respective photosensitizer was reported [62]. A number of
isotypes of immunoglobulin G bind through the Fc region
to protein A, which is expressed and localized as a typical
cell wall protein by quite few MRSA strains. The amount of
protein A embedded in the cell wall areas can vary among
these strains [69]. A close relationship between protein A
amount and inactivation efficacy was observed in the use
of the immunoglobulin G-tin(IV)chlorine e6 conjugate [62].
Despite many promising in vitro results, antibody targeting
antibacterial therapy has only had little real success in either
antibacterial PDT or cancer therapy. There are a number
of problems associated with antibody-based photodynamic
therapies, including difficulty to achieve specific antibodies
thatalsodisplayhighaffinity,inconsistentexpressionoftarget
antigens, and difficulty to internalize antibodies by the same
cells [70].
The possibility of using a bacteriophage to deliver the
photosensitizer tin(IV)chlorine e6 (SnCe6) to a serial strain
of S. aureus was also investigated [64]. Substantial inactiva-
tions of both MRSA and vancomycin-intermediate strains
were achieved with low concentrations of the conjugate
(1.5𝜇g/mL SnCe6) and low light doses (21J/cm
2). Under
these conditions, the viability of human epithelial cells in
the absence of bacteria was largely unaffected. On the molar
equivalent basis, the conjugate was more effective than the
unconjugated SnCe6, and bacterial inactivation was not
growth phase dependent. Furthermore, the conjugate was
effective against vancomycin-intermediate strains even after
growth in vancomycin [64]. These results indicated that a
bacteriophage might be used to deliver a photosensitizer
to a target organism, resulting in improving efficiency and
specificity in inactivation of the MRSA and other organisms,
which are desirable in the photodynamic therapy of infec-
tious diseases.
Another method was demonstrated to target MRSA by
taking advantage of its most common resistance mechanism
[65]. A specific enzyme-activated structure (𝗽-LEAP) was
developed, for which two phenothiazinium photosensitiz-
ers (EtNBS-COOH) were combined to the side chains of
cephalosporin. The two photosensitizers were quenched in
the uncleaved construct due to close proximity to each
other, but were activated through cleavage of the lactam
ring by beta-lactamase, which was synthesized only by
resistant strains. The selectivity of 𝗽-LEAP was demon-
strated through coculture experiments with human foreskin
fibroblasts (HFF-1) and MRSA strain. There was only little
nonspecific uptake of 𝗽- L E A Pb yt h eH F F - 1c e l l si nt h e
presence of MRSA, while the MRSA stain had far greater
𝗽-LEAP uptake [65]. This novel targeting strategy of the
resistance mechanism itself has, besides the specificity for
enzyme-mediatedresistantmicrobia,thepotentialadvantage
to distinguish between human and microbial cells.
7. Microorganism Strain Selective and
Antimicrobial PDT Resistant
Compared with traditional antibiotic therapy, microbes,
including MRSA, rarely develop resistance to antimicrobial
PDT. However, Grinholc et al. [71] recently demonstrated
that biofilm not producing S. aureus strains was much
more sensitive to PDT than to their slime-producing iso-
lates. In addition, neither correlation between antibacterial
PDT effectiveness and the antibiotic resistance pattern of
the different strains, nor correlation between photodynamic
inactivation efficacy and differences within proteins profiles
c o u l db ed e m o n s t r a t e d[ 71]. Possibly biofilm produced by
bacterium that obstructs the photosensitizer penetrating
into bacterial cells plays a role in resistance to PDT. The
effect of extracellular slime on photodynamic inactivation
o fb a c t e r i aw a sa l s oa n a l y z e db ya n o t h e rg r o u p[ 72], who6 BioMed Research International
reported that extracellular slime significantly influenced the
sensitizer uptake by the S. aureus cells. However, biofilm
nonproducing strains could also be found with elevated
resistance to PDT, and strains with a similar uptake possess
significantlydifferentsusceptibilitytoPDT[73].Thedifferent
uptakeduetoextracellularslimedidnotdeterminethestrain
dependence of PDT solely.
Efflux mechanisms have been recognized as important
components of microbial resistance of MRSA to various
classes of antibiotics. NorA efflux pump as one of the
multidrug resistance pumps (MDRs) has the ability to
expel a variety of structurally diverse compounds [74].
The uptake levels of phenothiazinium-based sensitizers MB,
TBO, and 1,9-dimethylmethylene blue (DMMB) by various
strains of S. aureus were showed to be proportional to
levels of NorA expression [75]. This suggested that MDRs
were able to pump the photosensitizer out of the cells
and thereby lessen the photoinactivity. However, the uptake
level of non-phenothiazinium-based photosensitizer proto-
porphyrindiarginatewasobservednottobeaffectedbyNorA
expression levels [73]. And the MDR inhibitor reserpine did
not affect the bactericidal activity either [73]. Therefore, the
efflux mechanism might not influence the uptake level of all
photosensitizers or the efficiency of MRSA inactivation.
Despitenumerousreportsdemonstratingthatavarietyof
photosensitizers can be used to inactivate S. aureus strains
including MRSA, some sensitizers show little or no bacte-
ricidal effect towards several strains [71]. The mechanism
responsible for strain-dependent inactivation and photody-
namic resistance has not yet been definitively identified.
8. Present Problems and Future Works
Due to the requirement that light should be delivered to the
microorganism,indicationsforantimicrobialPDTforMRSA
are the treatment of local, superficial skin and soft tissue
infections and arthritis. Topically applied photosensitizer
with subsequent irradiation has locally limited action of the
PDTandsideeffectssuchasallergiccontactsensitizationand
disturbance of the resident flora. Therefore, the severe side
effects of systemic administration of conventional antibiotic
for local MRSA infection are avoidable.
In order to attain high antibacterial activity with topical
antibacterial PDT, sufficient concentration of photosensi-
tizer at site (within bacterial cells or attached to the cell
membrane) is needed. A basic prerequisite for the effective
use of antimicrobial PDT is the uptake and/or binding of
the photosensitizer on the bacterial cell wall or plasma
membrane. Thus the design of the molecular structure and
the functional side chains of the photosensitizer [46, 48]
and the charge [44], as well as the manner in which the
photosensitizer is transported [20, 53–55, 59, 60], could
influence the efficiency of antimicrobial therapy. Cationic
photosensitizers with positive charge are usually more effi-
cientthantheirneutralandnegativechargedanalogueswhen
theyar eusedtoinactiva teGram-posi tiveandGram-nega tive
microorganisms. Significant alteration of the efficiency for
inactivating Gram-positive and Gram-negative bacteria can
be achieved through modifying benzo[a]phenothiazinium
dyes with one atom and one side chain, respectively [46, 48].
Systemic administration of photosensitizers after incorpo-
ration into lipophilic delivery systems, such as liposomes,
oil emulsions, or cyclodextrin inclusion complexes, can
minimize precipitation in the bloodstream or aggregation
in a polar circumstance, which reduces PDT therapeutic
efficiency. Photosensitizers encapsulated in liposomes and
micelles or loaded into hydrogel achieved better inactivation
of MRSA for local application of PDT to inactivate MRSA
in vitro. Additionally, combining cationic modification and
delivery system of polymer was believed to increase the
efficacy of inactivation [76].
Moreover, in order to improve specificity, targeting pho-
tosensitizers specifically to a certain type of microorgan-
isms was tested. Those targeting systems which have shown
promise in laboratory included chemical modification of the
photosensitizer itself, drug delivery strategy optimization,
the usage of antibodies and bacteriophage, and conjugation
withtraditionalantibiotic[61–65].Aswellasachievingbetter
selectivity, another advantage of using a targeted photo-
sensitizer is the increased antimicrobial efficiency. That is
because, following binding of the targeted photosensitizer to
theorganism,subsequentirradiationresultsinthegeneration
of ROS only in the vicinity of the pathogen and not at
extraneous sites. Consequently, less photosensitizer needs
to be applied, and because there is less attenuation of the
incident light by unbound photosensitizer, a lower light dose
can be used. However, a variety of disadvantages can hamper
effective photodynamic inactivation. For instance, the very
high molecular weight of such photosensitizer complexes
may inhibit penetration of the upper layers of the epidermis
needed for effective treatment of superficial skin MRSA
infections. Also alterations of the binding epitopes on the
protein surface of MRSA could result in a loss of antibody
recognition and thus in a loss of photodynamic activity.
At present, it is still unknown whether resistance to
P D Tw i l lb ed e v e l o p e db yM R S A .Th en u m b e ro fp h o t o -
sensitizer molecules binding to the surface of MRSA cells
is limited by biofilm formation and tunnel protein-deficient
mutation, and active outward transport of photosensitizer
canreducephotosensitizingefficiencytowardMRSA[72,74].
But in the studies from Grinholc et al. [71, 73], biofilm
nonproducing strains could also be found among S. aureus
strains with elevated resistance to PDT, and no associa-
tion between photodynamic inactivation efficacy and the
antibiotic resistance pattern (MDRs) of the different MRSA
strains or the antibiotic-sensitive MSSA strains could be
demonstrated. In addition to membrane structure and extra-
cellular biofilm, cellular repair systems or concentration of
antioxidantenzymesmightalsocontributetoresistance.ROS
inducing cellular necrosis and apoptosis play pivotal role in
photodynamic bacterial inactivation. However, the produc-
tion of ROS, particularly singlet oxygen, during irradiation
occurs only precisely at the location of the photosensitizer.
Singlet oxygen is only short lived in biological systems and
in parallel possesses only a very limited diffusion distance
( i np u r ew a t e ra b o u t1 𝜇m ,w h i l en om o r et h a n5 0 n mi n
the vicinity of protein-rich lipid milieu) [77]. To date, it isBioMed Research International 7
uncertain whether MRSA is capable of developing resistance
towards ROS through antioxidant enzymes activation or
other possible mechanisms. Nevertheless, the mechanism
responsibleforresistanceofcertainMRSAstrainsandMSSA
strains towards PDT thus needs to be definitively clarified in
the future.
9. Conclusion
It can be said that the optimized physicochemical properties
of photosensitizers as well as specific delivery systems will
decidewhetherantimicrobialPDTforMRSAinfectioncould
be accepted as an alternative way to traditional antibiotic
therapy. After further well-designed preclinical and clinical
studies, this novel therapeutic approach for MRSA infection
treatment may be established in clinical practices.
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